Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development - GBI Research Reports

Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development

Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development - GBI Research Reports
Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development
Published Dec 31, 2011
215 pages — Published Dec 31, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development, which provides insights into the global oncology therapeutics market and market forecasts until 2017. The report provides an in-depth analysis of major oncology indications, which includes breast cancer, colorectal cancer, Non-Hodgkins lymphoma (NHL), Non-Small Cell Lung Cancer (NSCLC), prostate cancer, ovarian cancer, cervical cancer and head and neck cancer. The report also includes insights into the oncology therapeutics R&D pipeline. It analyzes the competitive landscape in the oncology therapeutics market through analysis of M&A, licensing and co-development deals. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research finds that the global oncology therapeutics market was valued at $33.3 billion in 2010, increasing from $12.8 billion in 2002 to $33.3 billion at a CAGR of 12.7% during the review period 20022010. The market is projected to witness moderate growth of 5.7% during the forecast period 20102017 to reach $48.9 billion in 2017. The moderate growth of the market can be attributed to patent expiries for major drugs, including Taxotere (docetaxel) and Eloxatin (oxaliplatin), and the presence of strong targeted therapies in many therapeutic indications including breast cancer, colorectal cancer and NHL. The other major indications that have the presence of targeted therapeutics are expected to witness increased competition due to the launch of new targeted therapeutics during the forecast period. The pipeline for the oncology therapeutics market is strong and is expected produce targeted drugs with better safety and efficacy profiles. Competitive activity is high in the oncology therapeutics market and is expected to increase due to the need for new therapeutics to meet the unmet needs of late-stage cancer patients.

Scope

- Data and analysis on the global oncology therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the oncology therapeutics market from 2002-2010 with forecasts to 2017.
- Market data on the therapeutic landscape which covers breast cancer, colorectal cancer, NHL, NSCLC, prostate cancer, ovarian cancer, cervical cancer and head and neck cancer. This includes market size, market share, annual cost of therapy, treatment flow algorithm and branded and generic share.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global oncology therapeutics market which includes companies such as Roche, Sanofi, AstraZeneca, Eli Lilly, and Novartis.
- Key M&A activities and licensing and co-development agreements that took place from 2007-2011 in the global oncology therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and oncology therapeutics market segments poised for strong growth.
- Create a more tailored country strategy through the understanding of key drivers and barriers of the global oncology therapeutics market.
- Develop key strategic initiatives by understanding the key focus areas and top selling therapeutics of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

  
Source:
Document ID
GBIHC125MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents410
  List of Tables74
  List of Figures113
Oncology Therapeutics Market to 2017 - Introduction142
  GBI Research Report Guidance151
Oncology Therapeutics Market to 2017 - Market Overview1612
  Revenue Forecasts for Oncology Therapeutics Market161
    Revenue162
      Revenue Share by Geography182
      Brand and Generic Share202
    Annual Cost of Treatment221
  Treatment Usage Patterns232
  Drivers and Barriers for Oncology Therapeutics Market251
    Drivers251
      Increasing Prevalence of Cancer251
      Rapid Uptake of Targeted Therapeutics in Key Indications251
    Barriers261
      Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers261
      Moderate Growth in the US Market261
      Reimbursement Restrictions on Certain Oncology Drug Classes Restricts Market Growth271
Oncology Therapeutics Market to 2017 - Geographical Landscape2812
  The US281
    Revenue281
    Annual Cost of Treatment291
    Treatment Usage Patterns302
  Top Five Countries of Europe321
    Revenue321
    Annual Cost of Treatment331
    Treatment Usage Patterns342
  Japan361
    Revenue361
    Annual Cost of Treatment371
    Treatment Usage Patterns382
Oncology Therapeutics Market to 2017 - Therapeutic Landscape4090
  Breast Cancer401
    Introduction402
    Survival Rates by Stage421
    Symptoms421
    Treatment Flow433
    Revenue461
      Geographical Segmentation472
      Brand and Generic Share491
    Annual Cost of Treatment501
    Treatment Usage Patterns512
    Drivers and Barriers for Breast Cancer Therapeutics Market531
      Drivers531
      Barriers541
  Colorectal Cancer551
    Introduction551
    Survival Rates by Stage561
    Symptoms561
    Treatment Flow573
    Revenue601
      Geographical Segmentation612
      Brand and Generic Share631
      Annual Cost of Treatment641
    Treatment Usage Patterns652
    Drivers and Barriers for Colorectal Cancer Therapeutics Market671
      Drivers671
      Barriers671
  Non-Hodgkin s Lymphoma Therapeutics Market681
    Introduction681
    Survival Rates by Stage691
    Symptoms701
    Treatment Flow701
    Revenue712
      Geographical Segmentation731
      Generic Share741
    Annual Cost of Treatment751
    Treatment Usage Patterns761
    Drivers and Barriers for Non-Hodgkin s Lymphoma Market771
      Drivers771
      Barriers781
  Non-Small Cell Lung Cancer (NSCLC)781
    Introduction781
    Survival Rates by Stage791
    Symptoms791
    Treatment Flow802
    Revenue821
      Geographic Segmentation832
      Generic Share851
      Annual Cost of Treatment861
    Treatment Usage Patterns871
    Drivers and Barriers for NSCLC Therapeutics Market881
      Drivers881
      Barriers891
  Prostate Cancer Therapeutics Market891
    Introduction891
    Survival Rates901
    Symptoms901
    Treatment Flow902
    Revenue921
      Geographical Segmentation931
      Generic Share941
      Annual Cost of Treatment951
    Treatment Usage Patterns961
    Drivers and Barriers971
      Drivers981
      Barriers981
  Ovarian Cancer991
    Introduction991
    Survival Rates991
    Symptoms1001
    Treatment Flow1001
    Revenue1011
      Geographical Segmentation1022
      Branded and Generic Drug Share1041
      Annual Cost of Treatment1051
    Treatment Usage Patterns1061
    Drivers and Barriers1071
      Drivers1081
      Barriers1081
  Cervical Cancer1081
    Introduction1081
    Survival Rates1091
    Symptoms1101
    Treatment Flow1101
    Revenue1111
      Geographical Segmentation1122
      Generic Share1141
      Annual Cost of Treatment1151
    Treatment Usage Patterns1162
    Drivers and Barriers1181
      Drivers1181
      Barriers1181
  Head and Neck Cancer1191
    Introduction1191
    Survival Rates1201
    Symptoms1201
    Treatment Flow1211
    Revenue1221
      Geographical Segmentation1232
      Generic Share1251
      Annual Cost of Treatment1261
    Treatment Usage Patterns1272
    Drivers and Barriers1291
      Drivers1291
      Barriers1291
Oncology Therapeutics Market to 2017 - Product Pipeline Analysis13056
  Introduction1302
  R&D Pipeline - Breast Cancer1329
    Promising Drugs in the Pipeline1411
      T-DM11411
      Afinitor (everolimus)1411
      NeuVax (E75)1421
  R&D Pipeline - Colorectal Cancer1428
    Promising Molecules in the Pipeline1501
      Aflibercept1501
      KRX-0401 (perifosine)1501
  R&D Pipeline - NHL1511
    Non-Hodgkin s Lymphoma Therapeutics Pipeline1515
    Promising Pipeline Molecules1561
      LY3176151561
      Obinutuzumab1561
  R&D Pipeline - NSCLC1576
    Promising Pipeline Molecules1631
      Necitumumab (IMC-11F8)1631
      Tomtovok (Afatinib, BIBW 2992)1631
      MAGE-A31631
  R&D Pipeline - Prostate Cancer1646
    Promising Pipeline Molecules1701
      Aflibercept1701
      MDX-010 (Ipilimumab)1701
  R&D Pipeline - Ovarian Cancer1717
    Promising Pipeline Molecules1781
      Avastin (Approved in the EU)1781
      MORAb-0031781
  R&D Pipeline - Cervical Cancer1792
    Promising Pipeline Molecules1811
      V5031811
  R&D Pipeline - Head and Neck Cancer1813
    Promising Pipeline Products1841
      Tykerb1841
      TheraCIM1841
      Tomtovok1851
    Pipeline Analysis1851
Oncology Therapeutics Market to 2017 - Competitive Landscape1867
  Market Share Analysis1861
  Competitive Profiling1871
    F. Hoffmann-La Roche1871
      Overview1871
    AstraZeneca PLC1881
      Overview1891
    Eli Lilly and Company1901
      Overview1901
    Sanofi1911
      Overview1911
    Novartis AG1921
      Overview1921
Oncology Therapeutics Market to 2017 - Strategic Consolidations19314
  M&A Landscape1932
    M&A Deals by Year1951
    M&A Deals by Geography1961
    M&A Deals by Value1971
    M&A Deals by Deal Type1981
  R&D Licensing Agreements1991
    Deals by Year2001
    Deals by Geography2011
    Deals by Value2021
  Co-Development Agreements2031
    Deals by Year2041
    Deals by Geography2051
    Deals by Value2061
Appendix2079
  Market Definitions2071
  Abbreviations2072
  Research Methodology2092
    Coverage2091
    Secondary Research2101
    Primary Research2101
  Therapeutic Landscape2113
    Epidemiology-Based Forecasting2112
    Market Size by Geography2131
  Geographical Landscape2141
  Pipeline Analysis2141
  Competitive Landscape2141
    Expert Panel Validation2141
  Contact Us2141
  Disclaimer2141
  Sources2151

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development" Dec 31, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Oncology-Therapeutics-Market-to-2017-High-Unmet-Need-in-the-Management-and-Treatment-of-Metastatic-Cancers-to-Drive-Drug-Development-2115-316>
  
APA:
GBI Research Reports. (2011). Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development Dec 31, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Oncology-Therapeutics-Market-to-2017-High-Unmet-Need-in-the-Management-and-Treatment-of-Metastatic-Cancers-to-Drive-Drug-Development-2115-316>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.